The impact of reference pricing system on brand name’s prices : the case of Tunisia
AbstractMany policies are planned to face the increasing rate in health costs. In such circumstances and in order to reduce the pharmaceutical expenses, Tunisia adopted a reform of Health Insurance System. We study the effect of the introduction of reference pricing on pharmaceuticals’ price. In this study we use data for four molecules from IMS Health database. The data span from the third quarter 2002 to fourth quarter 2008. First, we study competition effect on brand-names’ price and generic one. We find that the brand name price’s drop is more important than the average price of generic. Then, we examine the effect of the introduction of reference pricing (RP) on prices. It shows that the brand name’s price decline after the introduction of RP and generic competition has an important role in this process. We find that the RP system has a strong effect in terms of reducing prices of pharmaceuticals; the effect is stronger for brand-name than generic versions. This confirms that the RP encourages generic competition and induces generic switching.
Download InfoIf you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
Bibliographic InfoPaper provided by Université Paris-Dauphine in its series Open Access publications from Université Paris-Dauphine with number urn:hdl:123456789/5347.
Date of creation:
Date of revision:
Contact details of provider:
Web page: http://www.dauphine.fr/en/welcome.html
Industrie pharmaceutique; Tunisie; économie de santé;
Find related papers by JEL classification:
- I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets
- L65 - Industrial Organization - - Industry Studies: Manufacturing - - - Chemicals; Rubber; Drugs; Biotechnology
- L51 - Industrial Organization - - Regulation and Industrial Policy - - - Economics of Regulation
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Patricia M. Danzon & Jonathan D. Ketcham, 2004.
"Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands, and New Zealand,"
Forum for Health Economics & Policy,
De Gruyter, vol. 7, pages 2.
- Patricia M. Danzon & Jonathan D. Ketcham, 2004. "Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands, and New Zealand," NBER Chapters, in: Frontiers in Health Policy Research, Volume 7, pages 1-54 National Bureau of Economic Research, Inc.
- Patricia M. Danzon & Jonathan D. Ketcham, 2003. "Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands and New Zealand," NBER Working Papers 10007, National Bureau of Economic Research, Inc.
- David Reiffen & Michael R. Ward, 2005. "Generic Drug Industry Dynamics," The Review of Economics and Statistics, MIT Press, vol. 87(1), pages 37-49, February.
- Zweifel, Peter & Crivelli, Luca, 1996. "Price Regulation of Drugs: Lessons from Germany," Journal of Regulatory Economics, Springer, vol. 10(3), pages 257-73, November.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Wendin-Malegdé Patrick Kaboré).
If references are entirely missing, you can add them using this form.